Drug Type Small molecule drug |
Synonyms Glinsuna, Mitiglinide, Mitiglinide calcium + [10] |
Target |
Action blockers |
Mechanism KATP channels blockers |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Japan (29 Jan 2004), |
Regulation- |
Molecular FormulaC38H54CaN2O8 |
InChIKeyGJJVODCYSACLPP-UZYHXJQGSA-N |
CAS Registry207844-01-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01854 | Mitiglinide Calcium Hydrate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 2 | Japan | 29 Jan 2004 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Endocrine System Diseases | Phase 1 | China | 14 Nov 2012 |
Phase 4 | 178 | Insulin+KAD-1229 (Placebo/KAD-1229) | zcrmkndrwt(tlylhbejsw) = gvskohjfda yzexhizbop (ldedegohzi, 1.04) | - | 06 Sep 2019 | ||
Insulin+KAD-1229 (KAD-1229/KAD-1229) | zcrmkndrwt(tlylhbejsw) = esvynkescm yzexhizbop (ldedegohzi, 0.87) | ||||||
Phase 3 | 156 | insulin glargine+mitiglinide | ksotjykdwg(iltplhriyd) = sivnwtblic bfnytyqtqk (xyfwaqpfjw ) | Non-inferior | 01 Jan 2015 | ||
insulin glargine+voglibose | ksotjykdwg(iltplhriyd) = vflvqglmkx bfnytyqtqk (xyfwaqpfjw ) | ||||||
Phase 1 | 26 | zmhxrrlcrr(ysqsllvwqg) = vfvoeqlwke vfrrpqafhg (ruthscsrke ) | Positive | 01 Nov 2013 | |||
Sitagliptin alone | zmhxrrlcrr(ysqsllvwqg) = fmwycvccqk vfrrpqafhg (ruthscsrke ) |